Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 145.46%.

  • Spero Therapeutics' EBIT Margin fell 74200.0% to 145.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 115.46%, marking a year-over-year decrease of 1181000.0%. This contributed to the annual value of 152.91% for FY2024, which is 1773900.0% down from last year.
  • Latest data reveals that Spero Therapeutics reported EBIT Margin of 145.46% as of Q3 2025, which was down 74200.0% from 17.22% recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' EBIT Margin peaked at 207.01% during Q4 2022, and registered a low of 1459.98% during Q1 2022.
  • Its 5-year average for EBIT Margin is 402.33%, with a median of 250.78% in 2025.
  • Over the last 5 years, Spero Therapeutics' EBIT Margin had its largest YoY gain of 12092700bps in 2022, and its largest YoY loss of -11941900bps in 2022.
  • Over the past 5 years, Spero Therapeutics' EBIT Margin (Quarter) stood at 1002.26% in 2021, then surged by 121bps to 207.01% in 2022, then crashed by -64bps to 74.07% in 2023, then crashed by -295bps to 144.41% in 2024, then dropped by -1bps to 145.46% in 2025.
  • Its EBIT Margin stands at 145.46% for Q3 2025, versus 17.22% for Q2 2025 and 250.78% for Q1 2025.